- Home
- VS vs CURX Comparison
VS vs CURX Comparison
Compare VS & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VS | CURX |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 7.9M |
| IPO Year | 2017 | 2024 |
Fundamental Metrics
Financial Performance| Metric | VS | CURX |
|---|---|---|
| Price | $1.07 | $4.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 23.7K |
| Earning Date | 11-13-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.97 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,183,415.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3711.30 | N/A |
| 52 Week Low | $0.75 | $0.18 |
| 52 Week High | $2.47 | $6.80 |
Technical Indicators
Market Signals| Indicator | VS | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 64.84 |
| Support Level | $1.01 | $3.91 |
| Resistance Level | $1.18 | $6.00 |
| Average True Range (ATR) | 0.06 | 0.34 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 19.13 | 72.13 |
Price Performance
Historical ComparisonAbout VS Versus Systems Inc.
Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.